Marshall Wace LLP Has $22.72 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Marshall Wace LLP decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 827,958 shares of the company’s stock after selling 5,278 shares during the quarter. Marshall Wace LLP owned about 0.44% of BridgeBio Pharma worth $22,719,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after buying an additional 19,978 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of BridgeBio Pharma by 28.6% in the fourth quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock valued at $994,000 after acquiring an additional 8,048 shares in the last quarter. Vanguard Group Inc. increased its position in BridgeBio Pharma by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after acquiring an additional 879,059 shares during the period. Exome Asset Management LLC increased its position in BridgeBio Pharma by 167.4% during the third quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock worth $5,372,000 after acquiring an additional 132,093 shares during the period. Finally, Barclays PLC raised its stake in BridgeBio Pharma by 31.9% in the 3rd quarter. Barclays PLC now owns 545,008 shares of the company’s stock worth $13,876,000 after purchasing an additional 131,743 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BBIO shares. Citigroup raised their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 24th. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Scotiabank increased their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Finally, HC Wainwright raised their price target on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

BridgeBio Pharma Stock Up 0.1 %

BridgeBio Pharma stock opened at $33.87 on Friday. The stock has a market cap of $6.44 billion, a PE ratio of -11.88 and a beta of 1.08. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $39.47. The business’s 50-day moving average price is $33.79 and its two-hundred day moving average price is $30.11.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. As a group, analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 326,932 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the sale, the chief executive officer now directly owns 5,371,515 shares in the company, valued at $194,932,279.35. This trade represents a 5.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrea Ellis sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the sale, the director now directly owns 12,000 shares in the company, valued at $408,600. The trade was a 71.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,694,739 shares of company stock worth $327,308,651. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.